Dose-Finding of Alfentanil for Hysteroscopy Under Remimazolam Sedation in Obese and Normal-Weight Patients: An Up-and-Down Trial.

Authors

Jindi Cao, Jinghui Ma, Jingyan Chen, Jie Zou, Yongxin Liang, Xue Dong

Published in

Drug design, development and therapy. Volume 20. Pages 623136. Epub Sep 08, 2026.

Abstract

Hysteroscopy is a minimally invasive procedure with rapid recovery. However, obesity may alter opioid pharmacokinetics and pharmacodynamics, and optimal alfentanil dosing remains uncertain. This study estimated the median effective dose (ED₅₀) and explored the 95% effective dose (ED₉₅) of alfentanil for suppressing predefined procedural responses during hysteroscopy under remimazolam sedation in obese and normal-weight patients.
This was an up-and-down sequential allocation trial. Patients were classified as obese or normal-weight according to body mass index (BMI). Recruitment and dose allocation were conducted independently within each group until seven crossover pairs were obtained. Alfentanil was administered initially at 10 μg/kg, with subsequent doses adjusted using a 1 μg/kg step size according to the preceding patient's response. Remimazolam was administered as a 0.4 mg/kg bolus followed by infusion at 1 mg/kg/h, titrated to maintain a bispectral index (BIS) of 40-60. The ED50 was initially estimated using the modified Dixon up-and-down method, followed by probit regression to estimate model-derived ED₅₀ and exploratory ED₉₅.
Sixty patients (31 normal-weight, 29 obese) were enrolled. Probit regression estimated an ED₅₀ of 9.71 μg/kg (95% confidence interval [CI], 7.81-12.26) in obese patients and 13.67 μg/kg (95% CI, 12.77-15.07) in normal-weight patients (P = 0.001). The corresponding ED₉₅ estimates were 12.57 μg/kg (95% CI, 10.92-28.28) and 16.24 μg/kg (95% CI, 14.92-21.48), respectively. The wider confidence interval for ED₉₅ in obese patients indicated limited precision.
The total-body-weight (TBW)-normalized ED₅₀ of alfentanil was significantly lower in obese than in normal-weight patients (P = 0.001). The ED₉₅ estimates are model-based and carry substantial uncertainty; no formal hypothesis test was performed for ED₉₅ comparisons. Close respiratory monitoring and individualized titration remain necessary.

PMID:
42732300
Bibliographic data and abstract were imported from PubMed on 13 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.